| Name | Title | Contact Details |
|---|
Circle Health Services, now affiliated with The Centers for Families and Children, is a nonprofit Federally Qualified Health Center (FQHC) that provides high-quality health care and related services to individuals and families regardless of their ability to pay. The Circle Health Services community health center, located at 12201 Euclid Avenue, is a 34,000 sq. ft. facility equipped with 18 examination rooms, five dental chairs, multiple group and individual therapy rooms, and an in-house pharmaceutical dispensary. The health center offers Adult and Pediatric Primary Care, a Teen/Reproductive Health Clinic, Dental Services, Behavioral Health Clinic, HIV Services, Dental Services, and Project DAWN (Deaths Avoided with Naloxone). Circle Health also operates a mobile syringe exchange program. Today, through its affiliation with The Centers for Families and Children, Circle Health operates under a shared leadership structure, which allows the organizations integrate behind-the-scenes administrative and operational support work and provide employees of both organizations access to the same benefits and professional development. Together, the organizations serve nearly 30,000 people and have more than 600 employees.
BetterVet is a national full-service mobile veterinary practice that provides expert vet services and telemedicine to reduce pets fear and stress. Our skilled mobile veterinarians offer a wide range of services in the comfort of your home, including i...
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Stockamp delivers: Stockamp helps high-performing hospitals reach the pinnacle of financial and operational excellence. We invented and perfected the science of revenue cycle management for hospitals and health systems, based on our unmatched
PINNACLE CBO is a Lakewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.